Skip to content
Buy This GLP
← Research
Evidence

Tirzepatide in Inflammatory Bowel Disease: Steroid Use Against the GLP-1 Class

In a matched U.S. cohort with inflammatory bowel disease, tirzepatide prescriptions were associated with less intravenous steroid use than other GLP-1 prescriptions.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team6 min read
Tirzepatide vs other GLP-1 drugs, adjusted hazard ratio1.0IV steroids0.81composite IBD outcome0.863,042 per matched cohort. No clear difference in surgery or hospitalization.

In the tirzepatide cardiovascular trial, researchers assigned two named drugs. This separate bowel disease study compared prescriptions from medical records, with several GLP-1 drugs grouped into one comparator [1].

What the records showed

Researchers matched 3,042 adults with inflammatory bowel disease in each group. Median follow-up was 540 days. Tirzepatide was associated with a lower hazard of intravenous steroid use (adjusted hazard ratio 0.81, 95% CI 0.68 to 0.94) [1].

The adjusted hazard ratio for the combined IBD outcome was 0.86 (95% CI 0.73 to 0.97). Hospitalization, emergency visits and bowel surgery did not show statistically clear differences.

What the comparison can establish

The records compare prescribing groups. Database matching cannot account for all differences in disease activity or why a clinician chose a drug. The study cannot establish that tirzepatide treats inflammatory bowel disease or that it improves outcomes versus a specific GLP-1 drug.

Frequently asked

Did the study find less bowel surgery with tirzepatide?
It found no statistically clear difference for surgery. The clearest association was with intravenous steroid use.

Sources

  1. [1] Patel KS, et al. (2026). Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study Intestinal Research. PMID 42717572

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence